1.

Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial

2.

Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial

1.

Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003

2.

Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003

1.

Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017

2.

Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017

3.

Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017

4.

Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017

5.

Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017

6.

Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017

7.

Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017

1.

Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium

2.

Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium

1.

Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium

2.

Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium

1.

Fig 6 -

2.

Fig 6 -

3.

Fig 6 -

4.

Fig 6 -

5.

Fig 6 -

6.

Fig 6 -

7.

Fig 6 -

8.

Fig 6 -

9.

Fig 6 -

1.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

2.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

3.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

4.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

5.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

6.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

7.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

8.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

9.

Distribution of the number of colistin-resistant Enterobacterales species by One Health sector and country.

1.

S2 Fig -

2.

S2 Fig -

3.

S2 Fig -

4.

S2 Fig -

5.

S2 Fig -

6.

S2 Fig -

7.

S2 Fig -

8.

S2 Fig -

9.

S2 Fig -

1.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

2.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

3.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

4.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

5.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

6.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

7.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

8.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

9.

Global view of BLAST comparisons between the mcr -harboring sequences and the most similar reference plasmid sequence (in grey) according to blastn.

1.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

2.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

3.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

4.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

5.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

6.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

7.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

8.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.

9.

Virulence potential of ColR-E from different One Health sectors in Belgium and the Netherlands.